MICROBOT MEDICAL INC.

Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

15 10 2024 07:38:00 提供 Nasdaq GlobeNewswire

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

30 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

17 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

22 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

13 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

01 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

18 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

09 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial

08 7 2024 07:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial

03 7 2024 07:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

20 6 2024 07:25:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial

17 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

04 6 2024 15:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

03 6 2024 11:11:00 提供 Nasdaq GlobeNewswire

Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

03 6 2024 07:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

29 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Shares Status Following Recent Geopolitical Events

15 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

05 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

30 1 2024 06:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

18 1 2024 06:20:00 提供 Nasdaq GlobeNewswire